THIS ARTICLE/PRESS RELEASE IS PAID FOR AND PRESENTED BY University of Oslo - read more
A blood protein can reduce brain damage after a stroke
If you have a stroke, the protein FSAP may help to reduce the extent of paralyses and problems with speech.
Every year, about 12 million people suffer from a stroke worldwide. A stroke occurs suddenly and is caused by either a blood clot or a brain haemorrhage.
“Those who survive often sustain life-changing brain damage. In addition to the cost in human suffering, caring for these patients is very expensive for health care systems. It is therefore important that we find treatments that can be applied immediately after a stroke. For every minute that is lost, more of the brain is damaged,” Professor Sandip Kanse says.
He conducts research on a protein called FSAP at the Institute of Basic Medical Studies at the University of Oslo (UiO).
Scientists had already discovered that the amount of FSAP in the blood of patients increases after a stroke. Some people have a gene-mutation that causes them to have less FSAP, and this puts them at a higher risk of having a stroke.
“Therefore, in theory, FSAP is beneficial for stroke patients. So we wanted to investigate whether FSAP could be used as a treatment for stroke,” Kanse says.
Mice treated with FSAP after a stroke suffered less brain damage
Kanse and his team carried out experiments on mice whereby they removed the gene responsible for the production of FSAP from some of the mice.
A stroke was then induced in the mice.
“The mice that had had their FSAP gene removed suffered more brain damage than the normal mice. This shows that the FSAP-gene is important for the protecting the brain. We then tested what would happened if we treated the mice with FSAP-protein after a stroke. Our results show that their condition improved dramatically,” Kanse explains.
Simultaneous treatment with TPA and FSAP
The next step was to give the mice FSAP together with the standard drug TPA. The researchers wanted to find out whether FSAP could enhance the effect of the TPA treatment.
The findings were promising and show that treatment combining TPA and FSAP had a better effect than TPA alone. This study was recently published in the FASEB Journal.
but it only works in a third of all patients.
TPA must also be administered within 4.5 hours after the stroke – after this time limit, it can cause damage to the brain.
In 10 per cent of patients, TPA causes severe bleeding in the brain.
“In other words, only 30 per cent of stroke patients improve when given TPA. The alternative to this treatment is surgery, which requires instruments that can look into the brain and remove the blood clot via a catheter. Not all hospitals have equipment of this kind, so it is not always possible to carry out this type of surgery. Therefore there is a need to find alternative ways of treating strokes,” Professor Kanse says.
Diagnosis and treatment should start in the ambulance
Scientists at UiO have now also developed an agent that can stimulate the body to produce more active FSAP. It is easier to develop such an agent than to produce FSAP itself.
An article on this research project was recently published in ACS Chem Biol.
“We now need more research to find out if triggering the production of active FSAP will work as a treatment for stroke or not. Ideally, the diagnosis and treatment should start immediately in the ambulance itself,” says Kanse.
Berge-Seidl et al. Identification of a Phage Display-Derived Peptide Interacting with the N-Terminal Region of Factor VII Activating Protease (FSAP) Enables Characterization of Zymogen Activation, ACS Chem. Biol, 2022. DOI: 10.1021/acschembio.2c00538
- 12 million people suffer a stroke each year worldwide
- The most common symptoms of a stroke are: paralysis on one side of the face and/or on one side of the body in an arm or leg, and trouble with language and speaking
- One in three people die of a stroke
- A third survive, but with lasting brain damage
- The last third survive without major problems afterwards
This article/press release is paid for and presented by the University of Oslo
This content is created by the University of Oslo's communication staff, who use this platform to communicate science and share results from research with the public. The University of Oslo is one of more than 80 owners of ScienceNorway.no. Read more here.
See more content from the University of Oslo:
Research breakthrough: Antiviral medication could be used to treat children with type 1 diabetes
Did author Knut Hamsun ever feel guilt for openly supporting the Nazis?
Is it OK for states to independently enforce international rules?
A digital reconstruction of the Gjellestad Viking ship will be complete within the next year
Researchers are testing a new treatment option for Burning Mouth Syndrome using capsaicin from chili peppers
Are elite athletes like zombies who can perform on autopilot?